STAT

A shot-in-the-dark email leads to a century-old family treasure — and hope of cracking a deadly flu’s secret

Century-old pathology samples, passed down through generations, may rewrite the history of the 1918 Spanish flu — altering our understanding of when it began and how it spread.

Late one night Michael Worobey began poking around on the internet, looking for descendants of a World War I British military doctor named William Rolland.

Rolland, a pathologist, had written a report in 1917, the year before the start of the Spanish flu. It described cases of British soldiers in France who had contracted an unusually fatal respiratory illness. Worobey, an evolutionary biology professor with a particular interest in the 1918 pandemic, wanted to know whether any of Rolland’s samples might still be lying about a century later.

Within a few hours, he had found a possible contact and fired off an email. Across the Atlantic, 5,000 miles away, a retired family physician in England’s picturesque Lake District received it. He replied immediately.

When Worobey read it, he was thunderstruck. “I almost fell out of my chair, for real,” he recalled. “I actually did cry real tears.”

The University of Arizona scientist had connected with a man named Jim Cox. And Cox just so happened to have in his possession a collection of human tissue slides that Rolland had handed down through the generations. Those slides, it turns out, could now help rewrite the history of the 1918 Spanish flu — altering our understanding of when it began and how it spread.

It makes for one heck of a story, one that could

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Drug Shortages, Medicare Spending On An Alzheimer’s Drug, And More
Medicare estimates a new Alzheimer’s drug could cost the program billions of dollars by next year — well beyond what Wall Street or the drug’s manufacturer project.
STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.

Related Books & Audiobooks